Novartis AG v. Union of India: The Battle Over Beta Crystalline Imatinib Mesylate

Overview

In a landmark departure from ordinary appellate procedure, the Supreme Court of India admitted and directly heard an appeal filed by Novartis AG against the order of the Intellectual Property Appellate Board (IPAB) — even though appeals from IPAB orders are ordinarily required to go first to the jurisdictional High Court. The IPAB had rejected Novartis's product patent claim over the beta crystalline form of Imatinib Mesylate, holding that it failed both the threshold test of "invention" under Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970, and the separate test of patentability under Section 3(d).

The Supreme Court dismissed Novartis's appeal and allowed the counter-appeals filed by two of the respondents, Natco Pharma Ltd. and the Cancer Patients Aid Association. Because the Court did not render a separate finding on these counter-appeals, it may reasonably be inferred that Novartis AG continues to hold the process patent rights for manufacturing the beta crystalline form of Imatinib Mesylate — as distinct from the product patent, which was denied.

Background and Prosecution History in India

To understand the Supreme Court's reasoning, it is useful to trace the procedural history of Novartis's Indian patent application for the beta crystalline form of Imatinib Mesylate.

1. Filing of the application. On July 17, 1998, Novartis AG filed Patent Application No. 1602/MAS/1998 in India, claiming priority from a Swiss application dated July 18, 1997, for an invention titled "Crystal Modification of N-Phenyl-2-Pyrimidineamine Derivative, Process for Its Manufacture and Its Use." The application drew pre-grant oppositions under Section 25(1) of the Patents Act from five parties: the Cancer Patients Aid Association, Natco Pharma Ltd., Cipla Ltd., Ranbaxy Laboratories Ltd., and Hetero Drugs Ltd.

2. Rejection by the Assistant Controller. By order dated January 25, 2006, the Assistant Controller of Patents rejected the application on four grounds:

• Anticipation. The invention was anticipated by the earlier Zimmermann patent (US Patent No. 5,521,184, a continuation-in-part of US Application Serial No. 08/042,232 filed September 9, 1993), by a May 1996 article in Nature Medicine, and by the USPTO's patent term extension certificate identifying Imatinib Mesylate (Gleevec) as the relevant product. Natco Pharma had also satisfactorily demonstrated that the salt naturally exists in the beta crystalline form, which is its most thermodynamically stable state.
• Obviousness. The claimed invention was obvious in light of the same prior publications.
• Non-patentability under Section 3(d). The application claimed merely a new form of a known substance, without demonstrating any significant improvement in therapeutic efficacy.
• Priority defect. The claim to Swiss priority was defective, as Switzerland was not a convention country on the date the application was made.

3. Writ petitions and transfer to the IPAB. Novartis challenged the Assistant Controller's order by way of writ petitions before the Madras High Court, since the IPAB had not yet been constituted. By order dated February 23, 2007, the High Court converted these writ petitions into statutory appeals.

4. Constitutional challenge to Section 3(d). In parallel, Novartis AG — both directly and through its power-of-attorney holder in India — filed separate writ petitions challenging the constitutionality of Section 3(d) itself, arguing that it was vague, conferred excessive discretion, and was inconsistent with India's obligations under TRIPS.

5. Transfer to the newly constituted IPAB. While the writ petitions were pending, the Government of India brought into force the provisions enabling appeals to the IPAB, effective April 2, 2007. Consequently, the High Court transferred all five pending appeals to the IPAB by order dated April 4, 2007.

6. Challenge to the Technical Member. Novartis sought to recuse the IPAB's Technical Member (Patents), who had previously served as Controller General of Patents, from hearing the appeals. This plea was dismissed by order dated July 20, 2007, on the basis of the doctrine of necessity.

7. Reconstitution directed by the High Court. Novartis challenged that dismissal before the Madras High Court, which directed the IPAB to constitute a special bench comprising the Chairman and Vice-Chairman, with liberty to seek assistance from scientific advisers if considered necessary.

8. Supreme Court intervention on composition. Natco Pharma filed a Special Leave Petition before the Supreme Court against this arrangement, contending that the statute required the presence of a technical member with appropriate specialised qualifications given the highly technical nature of the dispute. By order dated November 1, 2008, the Supreme Court directed reconstitution of the IPAB to include Dr. P.C. Chakraborti as Technical Member, and directed that the appeals be heard on a day-to-day basis commencing November 3, 2008.

9. The IPAB's decision. By judgment dated June 26, 2009, the IPAB allowed only the process claims relating to manufacture of the beta crystalline form, while rejecting the product and "use" claims.

10. Direct appeal to the Supreme Court. Novartis then approached the Supreme Court directly against the IPAB's judgment. After hearing all parties at length, the Supreme Court delivered a detailed and closely reasoned judgment on April 1, 2013, dismissing Novartis's appeal.

The Core Legal Question

The central issue before the Supreme Court was the relationship between two distinct statutory inquiries: whether a claimed product qualifies as an "invention" at all under Sections 2(1)(j) and 2(1)(ja), and whether — even if it does so qualify — its patentability can independently be denied under Section 3(d). The Court had to determine whether satisfying the definition of "invention" was sufficient in itself, or whether Section 3(d) operated as a further, independent enhanced-efficacy threshold that pharmaceutical substances must separately clear.

Timeline: From Zimmermann's Original Compound to the 2013 Judgment

Date	Event
April 28, 1994	Jürg Zimmermann files a US patent application for derivatives of N-phenyl-2-pyrimidine-amine, including Imatinib.
January 1, 1995	Effective date, under the Patents (Amendment) Act, 1999, from which Section 5 of the Patents Act, 1970 was retrospectively amended to permit claims for patents on substances intended for use as medicine or drugs, and Chapter IVA (Exclusive Marketing Rights) was inserted — bringing India into compliance with Article 70(8) and (9) of TRIPS.
January 1996	Cancer Research publishes "Inhibition of the Abl Protein-Tyrosine Kinase In Vitro and In Vivo by a 2-Phenylaminopyrimidine Derivative," co-authored by Zimmermann, discussing the antitumor properties of Imatinib and its methanesulfonate salt (Imatinib Mesylate).
May 28, 1996	USPTO grants Patent No. 5,521,184 (the "Zimmermann Patent").
July 18, 1997	Novartis AG files a Swiss application for a patent on the beta crystalline form of Imatinib Mesylate.
April 9, 1998	Novartis AG files an Investigational New Drug Application (IND #55,666) for Gleevec with the US FDA.
July 17, 1998	Novartis AG files Indian Patent Application No. 1602/MAS/1998, claiming Swiss priority.
November 30, 1998	Switzerland is notified as a convention country.
January 18, 2000	Novartis AG files a US patent application for the beta crystalline form of Imatinib Mesylate.
February 27, 2001	Novartis AG files a New Drug Application (NDA #21-335) for Imatinib Mesylate with the FDA, identifying Imatinib Mesylate as the active ingredient and asserting that the drug substance, formulation, and method of use are covered by US Patent No. 5,521,184.
May 10, 2001	FDA approves Gleevec (Imatinib Mesylate) 50 mg and 100 mg capsules.
July 3, 2001	US Patent No. 5,521,184 is granted a patent term extension of 586 days beyond its original expiry of May 28, 2013.
March 27, 2002	Novartis AG applies to the Indian Patent Office for Exclusive Marketing Rights (EMR).
November 10, 2003	EMR is granted to Novartis AG by the Indian Patent Office.
November 23, 2003	The US Court of Appeals reverses the USPTO's earlier rejection of the beta crystalline form patent.
January 1, 2005	Product patent protection is introduced in India.
May 17, 2005	The US patent for the beta crystalline form of Imatinib Mesylate is granted.
January 25, 2006	The Assistant Controller of Patents rejects Novartis's Indian application (1602/MAS/1998) following pre-grant oppositions.
February 23, 2007	Writ petitions against the Assistant Controller's order are converted into statutory appeals.
April 3, 2007	Provisions enabling appeals to the IPAB come into force.
April 4, 2007	The High Court transfers Novartis's appeals to the IPAB.
June 26, 2009	The IPAB allows only the process claims for manufacture of the beta crystalline form, rejecting the product and use claims.
April 1, 2013	The Supreme Court dismisses Novartis AG's appeal against the IPAB's judgment.

Concluding Note

The Novartis judgment remains one of the most consequential pharmaceutical patent decisions to emerge from an Indian court, chiefly for its interpretation of Section 3(d) as an efficacy-linked check on evergreening — the practice of seeking incremental patents on minor variants of known compounds. By reading Section 3(d) as operating independently of, and in addition to, the ordinary tests of novelty, inventive step, and industrial application, the Court signalled that pharmaceutical patentees in India must demonstrate genuine therapeutic advantage for new forms of known substances, not merely a difference in physical or chemical properties.

---

This article is intended for general informational purposes and does not constitute legal advice. Readers should consult a qualified patent attorney for guidance on specific matters arising under the Patents Act, 1970, or its judicial interpretation.